AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7734255 — intervention group
Group type: COMPARATOR
Intervention: 2% mepivacaine 20 ml mixed with contrast agent 20 ml, arm abducted
Number of subjects: 90
Study 2041002 — intervention group
Group type: EXPERIMENTAL
Intervention: Binaural hearing aid fitting
Number of subjects: 0
Study 2041002 — intervention group
Group type: COMPARATOR
Intervention: Monaural hearing aid fitting
Number of subjects: 0
Study 6112602 — intervention group
Group type: EXPERIMENTAL
Intervention: D-penicillamine (600 mg daily)
Number of subjects: 55
Study 6112602 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 31726240 — intervention group
Group type: EXPERIMENTAL
Intervention: Multisensory linear
Number of subjects: 85
Study 31726240 — intervention group
Group type: EXPERIMENTAL
Intervention: Multisensory random
Number of subjects: 85
Study 31726240 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual linear
Number of subjects: 85
Study 31726240 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual random
Number of subjects: 85
Study 31726240 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 85
Study 30516413 — intervention group
Group type: EXPERIMENTAL
Intervention: Power brush/irrigator/mouthrinse routine
Number of subjects: 51
Study 30516413 — intervention group
Group type: COMPARATOR
Intervention: Dental prophylaxis followed by regular manual brushing
Number of subjects: 51
Study 28594575 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus calculator
Number of subjects: 0
Study 28594575 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus calculator (extended use from 4 to 8 months)
Number of subjects: 0
Study 28594575 — intervention group
Group type: COMPARATOR
Intervention: Control group (previously intensified treatment)
Number of subjects: 0
Study 25823544 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive blood pressure lowering (target SBP <140 mm Hg)
Number of subjects: 3243
Study 25823544 — intervention group
Group type: COMPARATOR
Intervention: Guideline-recommended blood pressure lowering (target SBP <180 mm Hg)
Number of subjects: 3243
Study 23609769 — intervention group
Group type: EXPERIMENTAL
Intervention: Ecstasy users (12)
Number of subjects: 38
Study 23609769 — intervention group
Group type: EXPERIMENTAL
Intervention: Ecstasy + amphetamine users (10)
Number of subjects: 38
Study 23609769 — intervention group
Group type: COMPARATOR
Intervention: Controls (26 for orientation tuning; 38 for contour detection)
Number of subjects: 38
Study 23609769 — intervention group
Group type: EXPERIMENTAL
Intervention: Ecstasy + amphetamine users (12)
Number of subjects: 38
Study 21410481 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 40
Study 21410481 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 19374211 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine (Group E, n = 30, dose = 10 mg)
Number of subjects: 60
Study 19374211 — intervention group
Group type: COMPARATOR
Intervention: Phenylephrine (Group P, n = 30, dose = 80 microg)
Number of subjects: 60
Study 19374211 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine (Group E)
Number of subjects: 60
Study 19374211 — intervention group
Group type: COMPARATOR
Intervention: Phenylephrine (Group P)
Number of subjects: 60
Study 17919246 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapy (group II)
Number of subjects: 26
Study 17919246 — intervention group
Group type: COMPARATOR
Intervention: Michigan splint (group I)
Number of subjects: 26
Study 15119720 — intervention group
Group type: EXPERIMENTAL
Intervention: Loop technique
Number of subjects: 45
Study 15119720 — intervention group
Group type: COMPARATOR
Intervention: Holder technique
Number of subjects: 45
Study 11326796 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium intake of 900 mg/day
Number of subjects: 0
Study 9565434 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive use of SnMP (6 micromol/kg birth weight, intramuscularly)
Number of subjects: 86
Study 9565434 — intervention group
Group type: COMPARATOR
Intervention: Therapeutic use of SnMP (6 micromol/kg birth weight, intramuscularly)
Number of subjects: 86
Study 8200238 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular diet on the first postoperative morning (Group 1)
Number of subjects: 64
Study 8200238 — intervention group
Group type: COMPARATOR
Intervention: Traditional feeding method (Group 2)
Number of subjects: 64
Study 3310631 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate therapy, 1 g four times daily
Number of subjects: 143
Study 3310631 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 143
Study 3310631 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate therapy, 1 g twice daily to 1 g four times daily (long-term)
Number of subjects: 143
Study 29895557 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg daily
Number of subjects: 50
Study 29895557 — intervention group
Group type: COMPARATOR
Intervention: Control (standard treatment without empagliflozin)
Number of subjects: 50
Study 27183970 — intervention group
Group type: EXPERIMENTAL
Intervention: Vectra® 3D (54.45 mg/ml of dinotefuran, 396.88 mg/ml of permethrin and 4.84 mg/ml of pyriproxyfen)
Number of subjects: 24
Study 27183970 — intervention group
Group type: EXPERIMENTAL
Intervention: Vectra® 3D
Number of subjects: 24
Study 27183970 — intervention group
Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 24
Study 25348121 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 min conditioned stimulus (CS) during slow wave sleep (SWS)
Number of subjects: 96
Study 25348121 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 min conditioned stimulus (CS) during wakefulness
Number of subjects: 96
Study 25348121 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 min conditioned stimulus (CS) during SWS
Number of subjects: 96
Study 25348121 — intervention group
Group type: COMPARATOR
Intervention: 10 min irrelevant tone (control stimulus, CtrS) during SWS
Number of subjects: 96
Study 25348121 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 96
Study 23533252 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine
Number of subjects: 19
Study 23533252 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.375% bupivacaine
Number of subjects: 19
Study 23533252 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine
Number of subjects: 19
Study 21040167 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-transplantation dosing guided by a 2-hour (C(2) ) level (T2 group)
Number of subjects: 84
Study 21040167 — intervention group
Group type: COMPARATOR
Intervention: Standard dosing (control group)
Number of subjects: 84
Study 18369537 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorzolamide b.i.d. (08.00 and 20.00)
Number of subjects: 15
Study 18369537 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorzolamide t.i.d. (08.00, 16.00 and 20.00)
Number of subjects: 15
Study 18369537 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorzolamide t.i.d. (18.00)
Number of subjects: 15
Study 18369537 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorzolamide b.i.d. (18.00)
Number of subjects: 15
Study 17053765 — intervention group
Group type: EXPERIMENTAL
Intervention: Phlebodia 600
Number of subjects: 30
Study 14575375 — intervention group
Group type: EXPERIMENTAL
Intervention: 99mTc HMPAO lung scan
Number of subjects: 20
Study 14575375 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy men)
Number of subjects: 20
Study 11305226 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoral appliance therapy (daily use) during Phase I (6 months) and Phase II (6 months)
Number of subjects: 20
Study 11305226 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoral appliance therapy (daily use) during Phase II (6 months)
Number of subjects: 20
Study 11305226 — intervention group
Group type: COMPARATOR
Intervention: Control period (6 months prior to treatment)
Number of subjects: 20
Study 11305226 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase I and Phase II of intraoral appliance therapy
Number of subjects: 20
Study 9392574 — intervention group
Group type: EXPERIMENTAL
Intervention: Entacapone 200 mg
Number of subjects: 205
Study 9392574 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 205
Study 7949185 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Risk Group (SRG) with reinduction therapy
Number of subjects: 998
Study 7949185 — intervention group
Group type: COMPARATOR
Intervention: Standard Risk Group (SRG) without reinduction therapy
Number of subjects: 998
Study 7949185 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk Group (RG)
Number of subjects: 998
Study 7949185 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental Group (EG)
Number of subjects: 998
Study 7949185 — intervention group
Group type: COMPARATOR
Intervention: Late intensification in Risk Group (RG)
Number of subjects: 998
Study 7949185 — intervention group
Group type: COMPARATOR
Intervention: Prednisone poor response
Number of subjects: 998
Study 3190994 — intervention group
Group type: EXPERIMENTAL
Intervention: Single oral dose of 20 mg pholcodine
Number of subjects: 6
Study 3190994 — intervention group
Group type: EXPERIMENTAL
Intervention: Single oral dose of 60 mg pholcodine
Number of subjects: 6
Study 3190994 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic administration of 20 mg pholcodine 8 hourly for 10 days
Number of subjects: 6
Study 30946381 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine group (0.5% ropivacaine, 40 mL, n=69)
Number of subjects: 132
Study 30946381 — intervention group
Group type: COMPARATOR
Intervention: Control group (no analgesic, n=63)
Number of subjects: 132
Study 28968871 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrivalent recombinant influenza vaccine (RIV4)
Number of subjects: 0
Study 28968871 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose, egg‐grown, quadrivalent‐inactivated influenza vaccine (IIV4)
Number of subjects: 0
Study 28968871 — intervention group
Group type: EXPERIMENTAL
Intervention: Both RIV4 and IIV4
Number of subjects: 0
Study 25304132 — intervention group
Group type: EXPERIMENTAL
Intervention: Tralokinumab 300 mg subcutaneously every 2 weeks for 12 weeks
Number of subjects: 111
Study 23294343 — intervention group
Group type: EXPERIMENTAL
Intervention: Handwashing promotion
Number of subjects: 461
Study 23294343 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 461
Study 21630116 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentax‐AWS
Number of subjects: 32
Study 21630116 — intervention group
Group type: EXPERIMENTAL
Intervention: GlideScope
Number of subjects: 32
Study 21630116 — intervention group
Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 32
Study 19175188 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-tape viewing
Number of subjects: 91
Study 19175188 — intervention group
Group type: COMPARATOR
Intervention: Teaching booklet
Number of subjects: 91
Study 19175188 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (video-tape and teaching booklet)
Number of subjects: 91
Study 16861255 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg metoclopramide + 8 mg dexamethasone
Number of subjects: 3140
Study 16861255 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg metoclopramide + 8 mg dexamethasone
Number of subjects: 3140
Study 16861255 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg metoclopramide + 8 mg dexamethasone
Number of subjects: 3140
Study 16861255 — intervention group
Group type: COMPARATOR
Intervention: 0 mg metoclopramide + 8 mg dexamethasone
Number of subjects: 3140
Study 12508269 — intervention group
Group type: EXPERIMENTAL
Intervention: Short, intensive therapy (CCG-5911)
Number of subjects: 279
Study 12508269 — intervention group
Group type: COMPARATOR
Intervention: Moderate-dose chemotherapy (previous studies)
Number of subjects: 279
Study 12508269 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated LDH (> or = 500 IU/L) at diagnosis and young age (<5 years)
Number of subjects: 279
Study 10685739 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole (30 mg for 6 weeks)
Number of subjects: 17
Study 10685739 — intervention group
Group type: COMPARATOR
Intervention: Famotidine (40 mg for 6 weeks)
Number of subjects: 17
Study 9376181 — intervention group
Group type: EXPERIMENTAL
Intervention: Formestane (250 mg intramuscularly biweekly)
Number of subjects: 179
Study 9376181 — intervention group
Group type: COMPARATOR
Intervention: Megestrol acetate (160 mg orally daily)
Number of subjects: 179
Study 8227233 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg conventional metoprolol (M100)
Number of subjects: 12
Study 8227233 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 or 100 mg slow-release metoprolol CR (CR50, CR100)
Number of subjects: 12
Study 8227233 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 30846557 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenapanor (3 mg)
Number of subjects: 219
Study 30846557 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenapanor (10 mg)
Number of subjects: 219
Study 30846557 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenapanor (30 mg, down-titrated)
Number of subjects: 219
Study 30846557 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 219
Study 30846557 — intervention group
Group type: EXPERIMENTAL
Intervention: Pooled Tenapanor group
Number of subjects: 219
Study 29146660 — intervention group
Group type: EXPERIMENTAL
Intervention: Behaviour change intervention consisting of four physical activity consultations with a physiotherapist, supported by a handbook and pedometer.
Number of subjects: 60
Study 29146660 — intervention group
Group type: COMPARATOR
Intervention: Usual care only (control group).
Number of subjects: 60
Study 25772512 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized therapy with traditional Chinese medicine
Number of subjects: 24
Study 25772512 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized therapy with traditional Chinese medicine
Number of subjects: 24
Study 25772512 — intervention group
Group type: EXPERIMENTAL
Intervention: Best supportive care with traditional Chinese medicine
Number of subjects: 24
Study 25772512 — intervention group
Group type: COMPARATOR
Intervention: NCCN NSCLC treatment guidelines (Control group)
Number of subjects: 24
Study 22743641 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortoss
Number of subjects: 256
Study 22743641 — intervention group
Group type: COMPARATOR
Intervention: PMMA
Number of subjects: 256
Study 21532952 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright light treatment (2000, 4000, or 8000 lux for 1, 2, or 3 hours)
Number of subjects: 56
Study 21532952 — intervention group
Group type: COMPARATOR
Intervention: Moderate intensity light (2000 lux)
Number of subjects: 56
Study 18954199 — intervention group
Group type: EXPERIMENTAL
Intervention: Red color
Number of subjects: 5
Study 18954199 — intervention group
Group type: COMPARATOR
Intervention: Other achromatic and chromatic colors
Number of subjects: 5
Study 16186461 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal intervention physical activity strategy (PACE)
Number of subjects: 0
Study 16186461 — intervention group
Group type: COMPARATOR
Intervention: Standard physical activity advice (Control)
Number of subjects: 0
Study 12895189 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg ibuprofen (single oral dose)
Number of subjects: 32
Study 12895189 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 32
Study 10218357 — intervention group
Group type: EXPERIMENTAL
Intervention: Brandt's double cuff-tubes (Group 2)
Number of subjects: 116
Study 10218357 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard low-pressure tubes (Group 1)
Number of subjects: 116
Study 10218357 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group 3)
Number of subjects: 116
Study 8669404 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium supplementation
Number of subjects: 45
Study 8669404 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene supplementation
Number of subjects: 45
Study 8669404 — intervention group
Group type: COMPARATOR
Intervention: Placebo (no supplementation)
Number of subjects: 45
Study 1989743 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpleural bupivacaine-adrenaline mixture
Number of subjects: 42
Study 1989743 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular meperidine
Number of subjects: 42
Study 6613477 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal drain (187 patients)
Number of subjects: 383
Study 6613477 — intervention group
Group type: COMPARATOR
Intervention: No intraperitoneal drain (196 patients)
Number of subjects: 383
Study 30948449 — intervention group
Group type: EXPERIMENTAL
Intervention: Arachidonic acid (AA)
Number of subjects: 270342
Study 30948449 — intervention group
Group type: EXPERIMENTAL
Intervention: α-linolenic acid
Number of subjects: 270342
Study 28089728 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical with dermoscopic teleconsultation
Number of subjects: 454
Study 28089728 — intervention group
Group type: COMPARATOR
Intervention: Clinical teleconsultations (CTC)
Number of subjects: 454
Study 26562047 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer group‐based intervention group (IG)
Number of subjects: 543
Study 26562047 — intervention group
Group type: COMPARATOR
Intervention: Self‐management control group (CG)
Number of subjects: 543
Study 24170751 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive diabetes treatment
Number of subjects: 657
Study 24170751 — intervention group
Group type: COMPARATOR
Intervention: Conventional diabetes treatment
Number of subjects: 657
Study 24170751 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin dosage increase (10 units/day)
Number of subjects: 657
Study 24170751 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI increase (kg/m²)
Number of subjects: 657
Study 22661508 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (40 mg/day) for 1 month in statin-naïve patients
Number of subjects: 13
Study 22661508 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin in crossover study
Number of subjects: 13
Study 22661508 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 13
Study 19307970 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg morphine
Number of subjects: 188
Study 19307970 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg morphine
Number of subjects: 188
Study 19307970 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 188
Study 19307970 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg and 0.2 mg morphine
Number of subjects: 188
Study 17326830 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychiatric consultation embedded in a training programme
Number of subjects: 60
Study 17326830 — intervention group
Group type: COMPARATOR
Intervention: Care As Usual (only training aimed at recognition)
Number of subjects: 60
Study 15185764 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy
Number of subjects: 565
Study 15185764 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular stent treatment
Number of subjects: 565
Study 15185764 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 565
Study 11806217 — intervention group
Group type: EXPERIMENTAL
Intervention: Structum (chondroitin sulphate)
Number of subjects: 555
Study 11806217 — intervention group
Group type: COMPARATOR
Intervention: Control (matched patients)
Number of subjects: 555
Study 9571294 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 31
Study 9571294 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 31
Study 9571294 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 7974588 — intervention group
Group type: EXPERIMENTAL
Intervention: NASCET method
Number of subjects: 112
Study 7974588 — intervention group
Group type: EXPERIMENTAL
Intervention: ECST method
Number of subjects: 112
Study 7974588 — intervention group
Group type: EXPERIMENTAL
Intervention: CC method
Number of subjects: 112
Study 3382462 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg nimodipine
Number of subjects: 10
Study 3382462 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg nimodipine
Number of subjects: 10
Study 3382462 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31438581 — intervention group
Group type: EXPERIMENTAL
Intervention: Problematic cannabis use (measured by CAST scores)
Number of subjects: 648
Study 31438581 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 648
Study 28534723 — intervention group
Group type: EXPERIMENTAL
Intervention: Jugular venipuncture alpaca model (group M; n=18)
Number of subjects: 36
Study 28534723 — intervention group
Group type: COMPARATOR
Intervention: Control group (group C; n=18)
Number of subjects: 36
Study 26415790 — intervention group
Group type: EXPERIMENTAL
Intervention: Wenxin Keli
Number of subjects: 1200
Study 26415790 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1200
Study 23910069 — intervention group
Group type: EXPERIMENTAL
Intervention: Mivacurium 0.25 mg·kg(‐1) (NMB group)
Number of subjects: 38
Study 23910069 — intervention group
Group type: COMPARATOR
Intervention: Saline solution (NoNMB group)
Number of subjects: 38
Study 23910069 — intervention group
Group type: EXPERIMENTAL
Intervention: NMB group
Number of subjects: 38
Study 23910069 — intervention group
Group type: COMPARATOR
Intervention: NoNMB group
Number of subjects: 38
Study 21911782 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic variant TLL1 rs1503298
Number of subjects: 1043
Study 19918588 — intervention group
Group type: EXPERIMENTAL
Intervention: Zirconia-ceramic FDPs
Number of subjects: 59
Study 19918588 — intervention group
Group type: COMPARATOR
Intervention: Metal-ceramic FDPs
Number of subjects: 59
Study 16377964 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 g/kg of alcohol preload
Number of subjects: 15
Study 16377964 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 g/kg of alcohol preload
Number of subjects: 15
Study 16377964 — intervention group
Group type: COMPARATOR
Intervention: Placebo preload
Number of subjects: 15
Study 12843164 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA supplementation (25 mg/d)
Number of subjects: 24
Study 12843164 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 10639301 — intervention group
Group type: COMPARATOR
Intervention: High dose amiodarone
Number of subjects: 1073